The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: A systematic review and meta-analysis

Pharmacogenetics and Genomics

Volumn 22, Issue 8, 2012, Pages 642-645

  Terrazzino, Salvatore ^a   Quaglia, Marco ^a   Stratta, Piero ^a   Canonico, Pier L ^a   Genazzani, Armando A ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

ABCB1; allograft rejection; CYP3A5; meta analysis; pharmacokinetics; polymorphisms; renal transplantation; tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS;

ACUTE GRAFT REJECTION; DRUG BLOOD LEVEL; DRUG TROUGH LEVEL; GENETIC POLYMORPHISM; HETEROZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ALLELES; CYTOCHROME P-450 CYP3A; GENETIC ASSOCIATION STUDIES; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; P-GLYCOPROTEIN; SURVIVAL RATE; TACROLIMUS;

EID: 84863813155     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283557c74     Document Type: Review

References (10)

1. Van Gelder T, Hesselink DA. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome? Clin Pharmacol Ther 2010; 87:640-641.
2. Kuypers DRJ, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004; 75:434-447. (Pubitemid 38534564)
3. Takeuchi H, Matsuno N, Senuma K, Hirano T, Yokoyama T, Taira S, et al. Evidence of different pharmacokinetics including relationship among AUC, peak, and trough levels between cyclosporine and tacrolimus in renal transplant recipients using new pharmacokinetic parameter-why cyclosporine is monitored by C(2) level and tacrolimus by trough level. Biol Pharm Bull 2008; 31:90-94.
4. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43:623-653. (Pubitemid 38981845)
5. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 2010; 49:141-175.
6. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391. (Pubitemid 32268418)
7. Tang HL, Xie HG, Yao Y, Hu YF. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics 2011; 21:713-720.
8. Mai I, Perloff ES, Bauer S, Goldammer M, Johne A, Filler G, et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 2004; 58:548-553. (Pubitemid 39540460)
9. Koziolek MJ, Riess R, Geiger H, Thévenod F, Hauser IA. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int 2001; 60:156-166. (Pubitemid 32587550)
10. Naesens M, Lerut E, de Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DR. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 2009; 20: 2468-2480.